EVALUATION OF SERUM ALPHA-1-ANTITRYPSIN LEVELS IN 62 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE IN TEHRAN.


Abstract: Systemic lupus erythematosus (SLE) is an autoimmune and chronic inflammatory disease. It is believed that the attachment of autoantibodies to autoantigens leads to inflammation and kidney disorders. Alpha- 1-antitrypsin is an acute phase protein that neu­tralizes the deleterious effects of the proteolytic enzymes. The level of alpha-1-antitrypsin raises in inflammation. This enzyme is produced from those inflammatory cells (neutrophils) infiltrating to the involved sites. The goals of this study were the comparison of alpha-1-antitrypsin concentration in SLE patients and healthy controls and also the assessment of the enzyme levels in the pa­tients with and without kidney disorders. Sera of 62 patients (58 female and 4 male) and 32 healthy controls (28 female and 4 male) were collected and rocket immune electrophoresis (RIE) was employed for the determination of the enzyme. In the patients (aged 31+9, range 14-58 years) and in the control group (aged 31+10, range 14-57 years) alpha-1-antitrypsin levels were (139±46 mg/dl) and (117+22mg/dl) respectively (p<0.01).The alpha-1- antitrypsin levels in patients with kidney disorder were less than patients without kidney disorder (127+36 mg/dl and 151+52 mg/dl respectively, p<0.03). There was a significant association between low levels of alpha-1-antitrypsin and the presence of kidney disorder in SLE patients.